

Dominique Hubert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/499742/publications.pdf>

Version: 2024-02-01

18
papers

741
citations

623574

14
h-index

839398

18
g-index

19
all docs

19
docs citations

19
times ranked

802
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 220-227.	0.3	24
2	Rapid Improvement after Starting Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 64-73.	2.5	139
3	Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. <i>Pulmonary Therapy</i> , 2021, 7, 455-468.	1.1	8
4	Real-Life Safety and Effectiveness of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 188-197.	2.5	95
5	Pregnancy after lung and heartâ€“lung transplantation: a French multicentre retrospective study of 39 pregnancies. <i>ERJ Open Research</i> , 2019, 5, 00254-2018.	1.1	17
6	Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 114-121.	5.5	53
7	Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 89-95.	0.3	51
8	A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 636-642.	0.3	4
9	Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 388-391.	0.3	81
10	Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2017, 52, 190-197.	1.0	33
11	Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases. <i>PLoS ONE</i> , 2017, 12, e0187930.	1.1	21
12	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. <i>Infection and Drug Resistance</i> , 2016, Volume 9, 229-238.	1.1	53
13	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. <i>European Respiratory Journal</i> , 2016, 48, 249-252.	3.1	30
14	CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. <i>Pancreatology</i> , 2016, 16, 515-522.	0.5	6
15	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 204-212.	0.3	76
16	Maternal and perinatal outcomes of pregnancies in women with cystic fibrosis â€“ A single centre case-control study. <i>Respiratory Medicine</i> , 2016, 113, 22-27.	1.3	22
17	Discussion on genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. <i>Gastroenterology</i> , 2003, 125, 1286.	0.6	13
18	Management of assisted reproductive technologies in women with cystic fibrosis. <i>Fertility and Sterility</i> , 2001, 76, 1280-1281.	0.5	15